Accelerating research

and development of

new antibiotics and


Antimicrobials pipeline

An important aspect of the global problem on AMR is the lack of new drugs that can replace the increasingly ineffective set of antibiotics currently available. Worldwide, the pipeline for new antibiotics is limited because of scientific, regulatory and economic barriers. In response to this, multiple governmental and non-governmental organisation (NGO)-supported initiatives have been implemented at international and national level as an important step to boost the antibiotic research & development (R&D) pipeline.1 These initiatives include European Union/European Federation of Pharmaceutical Industries and Associations (EU/EFPIA)-supported Innovative Medicines Initiative (IMI),2 Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X),3Global Antibiotic Research & Development Partnership (GARDP),4 and the German-led G7/G20 Global AMR R&D Hub, in line with the national and EU strategies on AMR, the WHO Global Action Plan on AMR, and the UN General Assembly resolution in 2016.

1 Renwick MJ, Simpkin V, Mossialos E. Targeting innovation in antibiotic drug discovery and development: The need for a One Health – One Europe – One World Framework. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2016. (Health Policy Series, No. 45.)